The Effects of Stromal Vascular Fraction and Mesenchymal Stem Cells as Intra-articular Injection in Knee Joint Osteoarthritis

SCARM Institute, Tabriz, Iran

Status and phase: Withdrawn; Phase 2

Conditions: Osteoarthritis

Treatments: Biological: Placebo; Biological: Mesenchymal stem cell

Study type: Interventional

Funder types: Other

Identifiers

NCT03164083

SCARM-Osteoarthritis-001

Details and patient eligibility

About

Osteoarthritis of the knee is one of the most common causes of disability among elderly. As the disease progresses the cartilage become frustrated, surrounding bone react to become thicker and inflammation occurs in subchondral bone seen in T2-weighted MRI as increase in signal density. Patients are treated initially by pain management. In patients who don't response to first line treatment invasive treatment like total knee replacement is done. The investigators designed this clinical study with the aim of evaluating therapeutic effects of intra-articular injection of bone marrow Mesenchymal Stem Cells (MSC) and stromal Vascular Fraction (SVF) in patients with severe knee osteoarthritis

Full description

This is single center, randomized, triple blind phase II clinical study. Patients will be divided into two groups of case and control. All subjects will undergo bone marrow aspiration. Mesenchymal Stem Cells will be isolated from bone marrow and stromal Vascular Fraction fram lipoaspirate, cultured and transplanted back to the knee joint. Patients of case group will receive cell injection 1 and 4 months after bone marrow aspiration. Placebo will be administered in this group 6 months after the first injection. Patients of control group will receive placebo 1 and 4 months after bone marrow aspiration. They all receive cell injection 6 months after first placebo injection. Follow up visit will occur at 2 and 6 weeks, and 3 and 6 months after the first injection. Radiological exams will be performed before and 6 months after the first injection by MRI. Clinical quantitative assessment will measure joint function by the WOMAC index and pain by the visual analogue scale

Sex: All

Ages: 25 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Osteoarthritis diagnosed by MRI

Exclusion criteria

• Pregnancy or lactating
• Positive tests for HIV, Hepatitis C virus (HCV), Hepatitis C virus (HBV)
• Active neurologic disorder
• End organ damage
• Uncontrolled endocrine disorder

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

0 participants in 2 patient groups

mesenchymal stem cell

Experimental group

Description:

Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection

Treatment:

Biological: Mesenchymal stem cell

placebo

Experimental group

Description:

The patients who are in control group and underwent placebo injection

Treatment:

Biological: Placebo